Page 83 - Clinical Development News Today

Eli Lilly and Company and Boehringer Ingelheim announced the FDA approval of empagliflozin (Jardiance) for chronic kidney disease management on September 22, 2023.

Dublin, Sept. 22, 2023 (GLOBE NEWSWIRE) -- The

/PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in...

Axicabtagene ciloleucel achieved a complete metabolic response of 71% at 3 months versus 12% expected with standard of care among transplant ineligible patients with relapsed/refractory large B-cell lymphoma.

/PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, announced today...

Avantor, Inc. announced the creation of a new Scientific Advisory Board, which will provide strategic guidance and consult on the Companys mid- to long-term research and development efforts to...

/PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services for customers in the life sciences and...

Built upon seven years of real-world patient journey data, Belong.Life has recently announced the launch of its software as a service (SaaS)-based conversational artificial intelligence (AI) cancer clinical trial matching platform.

/PRNewswire/ -- The "Claudin 18.2-Targeted Immunotherapy: A Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from An...

SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and